XML 49 R22.htm IDEA: XBRL DOCUMENT v3.25.2
Share-Based Payments
 12 Months Ended
Apr. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments
Note 13: Share-Based Payments

We provide for equity-based incentives to be awarded to key employees and non-employee directors. Currently, these incentives consist of restricted shares, restricted stock units (which may also be referred to as deferred stock units), performance units, and stock options. During 2025, 2024, and 2023, these awards were administered through the 2020 Equity and Incentive Compensation Plan (the “2020 Plan”), which was approved by our shareholders in August 2020. Awards under the 2020 Plan may be in the form of stock options, stock appreciation rights, restricted shares, restricted stock units, performance shares, performance units, incentive awards, and other share-based awards, and they may be granted to our non-employee directors, consultants, officers, and other employees. Deferred stock units granted to non-employee directors vest immediately and, along with dividends credited on those deferred stock units, are paid out in the form of common shares upon termination of service as a non-employee director. At April 30, 2025, there were 3,389,099 shares available for future issuance under the 2020 Plan.
Under the 2020 Plan, we have the option to settle share-based awards by issuing common shares from treasury, issuing new Company common shares, or issuing a combination of common shares from treasury and new Company common shares.
Stock Options: Under the 2020 Plan, we granted 84,568 and 113,970 stock options during 2024 and 2023, respectively. No stock options were granted in 2025. Stock options granted in 2024 and 2023 vest ratably over a period of three years. The exercise price of all stock options granted was equal to the market value of the shares on the date of grant, and all stock options granted and outstanding have a contractual term of 10 years.
The fair value of each stock option is estimated on the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions for stock options granted:
20242023
Expected volatility25.0 %25.0 %
Dividend yield2.7 %3.1 %
Risk-free interest rate3.9 %3.6 %
Expected life of stock options (years)6.06.0
Expected volatility was calculated in accordance with the provisions of FASB ASC 718, Compensation – Stock Compensation, based on consideration of both historical and implied volatilities. The expected life of a stock option represents the period from the grant date through the expected exercise date of the option. This was calculated using a simplified method whereby the midpoint between the vesting date and the end of the contractual term is utilized to compute the expected term.
The following table is a summary of our stock option activity.
Number of 
Stock Options		Weighted-Average
Exercise Price
Outstanding at May 1, 2024656,959 $125.40 
Exercised(16,600)111.86 
Cancelled(2,820)132.17 
Outstanding at April 30, 2025
637,539 $125.72 
Exercisable at April 30, 2025
557,197 $123.29 
The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the stock option. The total intrinsic value for both stock options outstanding and exercisable was $1.4 at April 30, 2025, with an average remaining contractual term of 5.7 years and 5.3 years, respectively. The total intrinsic value of stock options exercised during 2025, 2024, and 2023 was $0.1, $0.1, and $8.6, respectively. The closing market price of our common stock on the last trading day of 2025 was $116.27 per share.
Compensation cost related to stock options is recognized ratably over the service period from the grant date through the end of the requisite service period. During 2025, 2024, and 2023, we recognized compensation cost of $1.9, $2.8, and $3.1, respectively. The annual tax benefit related to the stock option expense was $0.4, $0.7, and $0.7 for 2025, 2024, and 2023, respectively. As of April 30, 2025, we had unrecognized compensation cost of $1.1 related to the stock options that were granted in 2024 and 2023.
Cash received from stock option exercises was $1.9, $3.2, and $21.6 for the years ended April 30, 2025, 2024, and 2023, respectively.
Other Equity Awards: The following table is a summary of our restricted shares, deferred stock units, and performance units.
Restricted Shares
and Deferred
Stock Units		Weighted-Average
Grant Date Fair Value Per Share		Performance
Units		Weighted-Average
Grant Date Fair Value Per Share
Outstanding at May 1, 2024
256,757 $138.46 353,396 $140.20 
Granted186,895 111.44 157,329 117.74 
Vested(89,703)138.74 (102,792)135.53 
Forfeited(29,528)123.69 (53,827)134.05 
Outstanding at April 30, 2025
324,421 $124.16 354,106 $132.51 
The weighted-average grant date fair value of equity awards other than stock options that vested in 2025, 2024, and 2023 was $27.7, $36.5, and $30.6, respectively. The weighted-average grant date fair value of restricted shares, deferred stock units, and performance units is the average of the high and the low share price on the date of grant. The vesting date fair value of equity awards other than stock options that vested in 2025, 2024, and 2023 was $25.7, $46.9, and $36.2, respectively.
The following table summarizes the weighted-average fair values of the equity awards granted.
Year Ended April 30,Restricted Shares
and Deferred
Stock Units		Weighted-Average
Grant Date Fair Value Per Share		Performance
Units		Weighted-Average
Grant Date Fair Value Per Share
2025186,895 $111.44 157,329 $117.74 
2024155,354 143.60 117,312 153.20 
2023146,290 131.96 130,939 133.01 
The restricted shares and deferred stock units granted in 2025, 2024, and 2023 under our long-term incentive compensation program vest ratably over three years from the date of grant. The performance units granted in 2025, 2024, and 2023 vest three years from the date of grant and are converted to common shares upon vesting based on the performance achieved during the service period. The performance goals for the performance units granted in 2024 and 2023 are based on adjusted earnings per share and return on invested capital targets. The performance goals for the performance units granted in 2025 are based on adjusted earnings per share and average net sales growth. Dividend equivalents are accumulated on the performance units from the date of grant, but participants only receive payment if the awards vest.